Literature DB >> 28040834

Aldehyde dehydrogenase activity plays no functional role in stem cell-like properties in anaplastic thyroid cancer cell lines.

Mika Shimamura1, Tomomi Kurashige1, Norisato Mitsutake2, Yuji Nagayama3.   

Abstract

Recent studies have revealed that aldehyde dehydrogenase (ALDH) is a candidate marker for thyroid cancer stem cells, although its activity is flexible. The goal of this study is to clarify the functional significance of ALDH enzymatic activity on thyroid cancer stem cells properties in anaplastic thyroid cancer cell lines. In vitro sphere formation assay was used to judge the stemness of 4 anaplastic thyroid cancer cell lines (FRO, ACT1, 8505C, and KTC3). Two well-known ALDH inhibitors, N,N-diethylaminobenzaldehyde (DEAB) and disulfiram (DS), were first used. DEAB (50 μM) almost completely suppressed ALDH activity without affecting cell proliferation or spherogenicity. Lack of effect of ALDH suppression on spherogenicity was confirmed using shRNA for ALDH1A3, an ALDH isozyme predominantly expressed in anaplastic thyroid cancer cell lines. In contrast, an ALDH2 inhibitor DS (1 μM) inhibited spherogenicity but did not inhibit ALDH1A3 activity. Based on the recent article from another group reporting the importance of sonic hedgehog (Shh) signaling in ALDH activity and spherogenicity in thyroid cancer, the effects of the Shh inhibitor cyclopamine were also studied. Like DS, cyclopamine (1 μM) decreased spherogenicity but not ALDH activity. Finally, exogenous expression of ALDH1A3 in otherwise ALDH- TPC1 cells (a papillary thyroid cancer cell line) revealed no effect on spherogenicity. In conclusion, we here show no functional role for ALDH activity in thyroid thyroid cancer stem cells properties. That is, ALDH activity and spherogenicity are clearly dissociable. Further understanding of thyroid cancer stem cells biology in thyroid cancers remains necessary for the future development of thyroid thyroid cancer stem cells-targeted therapies.

Entities:  

Keywords:  Aldefluor assay; Aldehyde dehydrogenase; Cancer stem cells; Spherogenicity; Thyroid cancer

Mesh:

Substances:

Year:  2016        PMID: 28040834     DOI: 10.1007/s12020-016-1224-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  42 in total

1.  Studies on expression of aldehyde dehydrogenase in normal and cancerous tissues of thyroids.

Authors:  T Kurashige; M Shimamura; K Yasui; N Mitsutake; M Matsuse; M Nakashima; S Minami; S Eguchi; Y Nagayama
Journal:  Horm Metab Res       Date:  2014-09-02       Impact factor: 2.936

Review 2.  Cancer stem-like cells and thyroid cancer.

Authors:  Zhenying Guo; Heather Hardin; Ricardo V Lloyd
Journal:  Endocr Relat Cancer       Date:  2014-04-30       Impact factor: 5.678

Review 3.  Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.

Authors:  Vindhya Koppaka; David C Thompson; Ying Chen; Manuel Ellermann; Kyriacos C Nicolaou; Risto O Juvonen; Dennis Petersen; Richard A Deitrich; Thomas D Hurley; Vasilis Vasiliou
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

Review 4.  Thyroid cancer stem cells.

Authors:  Reigh-Yi Lin
Journal:  Nat Rev Endocrinol       Date:  2011-07-26       Impact factor: 43.330

5.  Stemness in human thyroid cancers and derived cell lines: the role of asymmetrically dividing cancer stem cells resistant to chemotherapy.

Authors:  Risheng Ma; Noga Minsky; Syed A Morshed; Terry F Davies
Journal:  J Clin Endocrinol Metab       Date:  2014-02-25       Impact factor: 5.958

6.  Retinoid signaling regulates breast cancer stem cell differentiation.

Authors:  Christophe Ginestier; Julien Wicinski; Nathalie Cervera; Florence Monville; Pascal Finetti; François Bertucci; Max S Wicha; Daniel Birnbaum; Emmanuelle Charafe-Jauffret
Journal:  Cell Cycle       Date:  2009-10-10       Impact factor: 4.534

7.  Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines.

Authors:  Mika Shimamura; Yuji Nagayama; Michiko Matsuse; Shunichi Yamashita; Norisato Mitsutake
Journal:  Endocr J       Date:  2014-02-15       Impact factor: 2.349

8.  The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis.

Authors:  Christel van den Hoogen; Geertje van der Horst; Henry Cheung; Jeroen T Buijs; Rob C M Pelger; Gabri van der Pluijm
Journal:  Clin Exp Metastasis       Date:  2011-06-07       Impact factor: 5.150

9.  Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.

Authors:  Y Nobuhara; N Onoda; Y Yamashita; M Yamasaki; K Ogisawa; T Takashima; T Ishikawa; K Hirakawa
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

Review 10.  Cancer Stem Cells in the Thyroid.

Authors:  Yuji Nagayama; Mika Shimamura; Norisato Mitsutake
Journal:  Front Endocrinol (Lausanne)       Date:  2016-02-29       Impact factor: 5.555

View more
  4 in total

Review 1.  Update of ALDH as a Potential Biomarker and Therapeutic Target for AML.

Authors:  Xiangchou Yang; Rongxin Yao; Hong Wang
Journal:  Biomed Res Int       Date:  2018-01-03       Impact factor: 3.411

2.  Transcriptional Expressions of ALDH1A1/B1 as Independent Indicators for the Survival of Thyroid Cancer Patients.

Authors:  Ying Cui; Yao Liu; Lan Mu; Yang Li; Gang Wu
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

Review 3.  Sonic Hedgehog Signaling in Thyroid Cancer.

Authors:  Xiulong Xu; Yurong Lu; Yi Li; Richard A Prinz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-30       Impact factor: 5.555

4.  Extensive lymphatic spread of papillary thyroid microcarcinoma is associated with an increase in expression of genes involved in epithelial-mesenchymal transition and cancer stem cell-like properties.

Authors:  Sohee Lee; Ja Seong Bae; Chan Kwon Jung; Woong Youn Chung
Journal:  Cancer Med       Date:  2019-09-09       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.